Cargando…

Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1

The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toi, Masakazu, Boyle, Frances, Im, Young-Hyuck, Reinisch, Mattea, Molthrop, David, Jiang, Zefei, Wei, Ran, Sapunar, Francisco, Grimes, Brenda R, Nabinger, Sarah Cassidy, Johnston, Stephen R D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847542/ https://www.ncbi.nlm.nih.gov/pubmed/36342342 http://dx.doi.org/10.1093/oncolo/oyac234

Ejemplares similares

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
por: Johnston, Stephen, et al.
Publicado: (2021)

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
por: Johnston, Stephen, et al.
Publicado: (2019)

Abemaciclib plus fulvestrant in East Asian women with HR+, HER2− advanced breast cancer: Overall survival from MONARCH 2
por: Toi, Masakazu, et al.
Publicado: (2022)

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials
por: Toi, Masakazu, et al.
Publicado: (2021)

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer
por: Paluch-Shimon, Shani, et al.
Publicado: (2023)

Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels
por: Masuda, Norikazu, et al.
Publicado: (2022)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer
por: Goetz, Matthew P., et al.
Publicado: (2020)

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
por: Sledge, George W., et al.
Publicado: (2019)

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial
por: Martin, Miguel, et al.
Publicado: (2022)

MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study
por: Zhang, Qing Yuan, et al.
Publicado: (2020)

Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
por: Inoue, Kenichi, et al.
Publicado: (2021)

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
por: Goetz, Matthew P., et al.
Publicado: (2021)

Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Takahashi, Masato, et al.
Publicado: (2021)

Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
por: Neven, Patrick, et al.
Publicado: (2021)

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
por: Hamilton, Erika, et al.
Publicado: (2022)

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
por: Rugo, Hope S., et al.
Publicado: (2020)

Are you treating ypN0 patient with adjuvant abemaciclib?
por: Toss, A., et al.
Publicado: (2023)

MonarchBase: the monarch butterfly genome database
por: Zhan, Shuai, et al.
Publicado: (2013)

Monarchs and Medicine
Publicado: (1899)

Less necessity of adjuvant S‐1 treatment in non‐monarchE‐eligible patients
por: Yu, Muhan, et al.
Publicado: (2023)

Abemaciclib for breast cancer
Publicado: (2020)

Monarch of the flute : the life of Georges Barrère /
por: Toff, Nancy
Publicado: (2005)

Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice
por: Ring, Alistair, et al.
Publicado: (2023)

An evaluation of the Monarch chemistry analyser
por: Berry, D. J., et al.
Publicado: (1989)

Clocks, cryptochromes and Monarch migrations
por: Kyriacou, Charalambos P
Publicado: (2009)

Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center
por: Dannehl, Dominik, et al.
Publicado: (2022)

Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China
por: Wei, Qiran, et al.
Publicado: (2023)

In Monarchs, Cry2 Is King of the Clock
por: Robinson, Richard
Publicado: (2008)

The genetics of monarch butterfly migration and warning coloration
por: Zhan, Shuai, et al.
Publicado: (2014)

Neo-sex Chromosomes in the Monarch Butterfly, Danaus plexippus
por: Mongue, Andrew J., et al.
Publicado: (2017)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Abemaciclib: A multi-functional radiation modifier
por: Naz, Sarwat, et al.
Publicado: (2019)

Do Healthy Monarchs Migrate Farther? Tracking Natal Origins of Parasitized vs. Uninfected Monarch Butterflies Overwintering in Mexico
por: Altizer, Sonia, et al.
Publicado: (2015)

How the monarch got its spots: Long-distance migration selects for larger white spots on monarch butterfly wings
por: Davis, Andrew K., et al.
Publicado: (2023)

Density estimates of monarch butterflies overwintering in central Mexico
por: Thogmartin, Wayne E., et al.
Publicado: (2017)

Density-dependence in the declining population of the monarch butterfly
por: Marini, Lorenzo, et al.
Publicado: (2017)

Aggression Is Induced by Resource Limitation in the Monarch Caterpillar
por: Collie, Joseph, et al.
Publicado: (2020)

Stimulus-dependent orientation strategies in monarch butterflies
por: Franzke, Myriam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dr0suafddc7k008mcbooka1jf7